5. Chapter Five: Wanting a Better Life
5.1. Professional Development
1. The sample size is the minimum required, a larger sample size with a multi-centre approach will be required to make a stronger inference.
2. Inability to determine precisely the duration of HIV infection as the disease is usually asymptomatic in the early stages.
3. Inability to do a comprehensive biochemical work-up of cardiovascular risks due to high cost.
4. Myocarditis is a potential pathogenic mechanism for left ventricular dysfunction in HIV positive patients, but histological evidence through cardiac biopsy is unavailable here.
5. Inability to do right sided cardiac catheterization which is the gold standard in diagnosis of pulmonary hypertension and right ventricular dysfunction..
6. Inability to do other more precise radiologic investigations of cardiac structure and function e.g.
tissue doppler imaging and CT scan of the heart due to prohibitive cost.
110 REFERENCE
1. The Joint United Nations, Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO). AIDS epidemic update, 2009 report.
2. UNDP-Human Development Report Geneva WHO 2005.
3. Federal Ministry of Health. National HIV Sero-prevalence Sentinel Survey. Abuja. Federal ministry of Health, 2010.
4. Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J et al. The Cardiovascular disease continuum validated: clinical evidence of improved patient
111 outcomes: part 1: pathophysiology and clinical trial evidence. Circulation 2006; 114:2850-2870.
5. Yach D, Hawkes C, Gould CI, Hofman KJ. The global burden of chronic diseases:
overcoming impediments to prevention and control. JAMA 2004; 291; 2616-2620.
6. Lawoyin TO, Asuzu MC, Kaufman J, Rotimi C, Owoaje E, Johnson L, et al. Prevalence of cardiovascular risk factors in an African urban inner city community. W Afr J Med 2002;
21: 208-211.
7. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: Part 1;General considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001; 104: 2746-2753.
8. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Furher J, Satten GA et al. Declining morbidity and mortality among patient with advanced HIV infection, N Engl J Med 1998;
338: 853-860.
9. Effros RB, Fletcher CV, Gebo K, Halter JB, Hazzard WR, Home FM. Aging and Infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis.2008; 47:542-553.
10. Muralikrishna G, Archana B, Wissam I K, and Alejandro B. Heart Disease in Patients with HIV/AIDS-An Emerging Clinical Problem. Curr Cardiol Rev. 2009 May; 5(2): 149–154.
11. Cammarosano C, Lewis W. Cardiac lesions in acquired immune deficiency syndrome (AIDS). J Am Coll Cardiol. 1985; 5:703.
12. Babaro G. Cardiovascular manifestations of HIV infection. JR Soc Med 2001:94:384-390.
13. Sani M.U, Okeahialam B.N. Epidemiology and pathogenesis of HIV Related heart Disease.
Niger J. Med. 2005; 14:255-260.
14. Currie PF, Jacob AJ, Foreman AR et al. Heart Muscle Disease Related to HIV Infection:
Prognostic implication. BMJ 1994:309:1605-1607.
112 15. Grunfeld C, Pang M, Doerrier W, Shigenaga J.K, Jensen P and Feingold K.R. Lipids, Lipoproteins, triglyceride clearance and cytokines in human immunodeficiency syndrome. J clin Endocrinol Metab 1992; 74; 1045-1052.
16. Bergersen BM, Sandvik L, Bruun JN, Tonstad S. Elevated Framingham score in HIV-positive patients on HAART: results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis.2004:23:635-630.
17. Friis-Moller N, Weber R, Riess P, Thiebaut R, Kirk O, d’Arminio MA, et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the D.A.D study. AIDS 2003, 17(8): 1179-1193.
18. Friis-Moller N, Sabin CA, Weber R, d’Arminio MA, El Sadr WM, Riess P, et al.
Combination antiretroviral therapy and risk of Myocardial infarction. N Engl J Med 2003, 349(21):1993-2003.
19. Friis-Moller N, Reiss P, Sabin C.A and D.A.D Study Group. Class of antiretroviral drugs and risk of myocardial infarction. N Engl J Med; 2007; 356; 1723-1735.
20. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patient with human immunodeficiency virus disease.
J Clin Endocrinol Metab 2007, 92(7):2506-2512.
21. James H.S. Cardiovascular Risks of Antiretroviral therapy. N Engl J Med 2007; 356; 1773-1775.
22. Centres for Disease Prevention and control (CDC). Pneumocystis Pneumonia- Los Angeles.
MMWR 1981; 30:250-252.
23. Masur H, Michelis MA, Greene JB, et al. An outbreak of community- aquired Pneumocystis carinii pnuemonia: initial manifestation of cellular immune dysfunction. N Eng J Med 1981; 305:1431-1438.
113 24. Friedman-Kien AE, Laubenstein L, Marmor M, et al. Kaposi's sarcoma and
Pneumocystis pneumonia among homosexual men in New York City and California.
MMWR Morb Mortal Wkly Rep 1981;30:305-308.
25. Curan JW, Lawrence DN, Jaffe H et al. Acquired immunodeficiency syndrome (AIDS) associated with transfusion. N Eng J Med 1984;310:69-75.
26. Oleske J, Cooper R, Minnerfor A et al. Immune deficiency syndrome in Children. JAMA 1983; 2345-2349.
27. Elliot JL, Hoppes WL, Platt MS et al. The acquired immunodeficiency syndrome and Mycobacterium avium cellulare bacteraemia in a patient with haemophilia. Ann Intern Med 1983; 98(3): 290-293.
28. Weber JN, Weiss RA. The virology of humman immunodeficiency viruses. Br. Med. Bull 1988; 44: 20-37.
29. Brun-vezinet F, Rey M, Katlama C, et al. Lymphadenopathy-associated virus type 2 in AIDS and AIDS- related complex. Clinical and virological features in four patients. Lancet 1987;1:128-132.
30. Marlink R, Kanki P, Siby T et al. Reduced rate of development after HIV-2 infection as compared to HIV-1. Science 1994; 265:1587- 1590.
31. Nasidi A, Harry TO. The Epidemiology of HIV/AIDS in Nigeria. Error! Hyperlink reference not valid.. Accessed May 2013.
32. Olaleye DO, Harry TO, Odaibo GN. The Virilogy and Dynamics of the epidemics. Error!
Hyperlink reference not valid. Accessed May 2013.
33. Alimonti J, Ball T, Fowke K. Mechanisms of CD4+ T lymphocyte cell death in human immunodeficiency virus infection and AIDS. J Gen Virol, 2003;84:1649-1661.
34. McDermott D, Zimmerman P, Guignards F, et al. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study(MACS) Lancet HIV-1998;352:866-870.
114 35. Smith C et al. Association between modifiable and non-modifiable risk factors and specific causes of death in the HAART era: The D.A.D study. Sixteenth conference on Retroviruses and opportunistic infections. Montreal. Abstract 145, 2009.
36. Carr A, Samaras K, Bhurton Law M, Freund J, Chisholm D, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12(7):F51-F58.
37. Note R, Maisonneuve C, Letteron P, Peytavin G, Djouadi F, Igoudjil A, Guimont M-C, Biour M, Pessayre D, Fromenty B: Mitochondrial and Metabolic Effects of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in Mice Receiving One of Five Single- and Three Dual-NRTI Treatments. Antimicrob Agents Chemother 2003, 47(11):3384-3392.
38. Mshelia RJ. Prevalence of Glucose intolerance and associated risk factors among HIV/AIDS patients on HAART at the Jos University Teaching Hospital, Jos. Part 11 National Postgraduate Medical College of Nigeria Dissertation 2008.
39. Kannel WB. Coronary risk factors: an overview.In: Willerson JT, Cohn JN, Eds, Cardiovascular Medicine. New York, NY: Churchill Livingstone; 1995: 1809-1828.
40. WHO. The World Health Report 2002 ‘Reducing the Risks and Promoting Healthy Life’
Geneva, WHO 2002.
41. Dahlof B, Cardiovascular disease risk factors: Epidemiology and Risk assessment. Am J Cardiol; 2010:105; Suppl: 3A-9A.
42. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345:
1291–1297.
43. Gillum RF. The epidemiology of cardiovascular disease in black Americans. N Engl J Med 1996; 335: 1597–1598.
115 44. Iwuala SO. Hypertension is the most common component of the metabolic syndrome in a cohort of NRTI based HAART treated patient-a preliminary report. Journal of International AIDS society, 2008; 11; 126.
45. Gazzaruso C, Bruno R, Garzanti A, Giordanetti S, Fratino P, Sachi P et al. Hypertension among HIV-infected patients: prevalence and relationship to insulin resistance and metabolic syndrome. Journal of Hypertension 2003; 21(7); 1377-1382.
46. Dominic CC, Scott AS, Chan R, Suzanne MR, Andy G, Cecilia S. Elevated Blood pressure in HIV-infected Individuals receiving HAART. HIV Clin Trials 2003:4(6):411-416.
47. Bergersen BM, Sandvik L, Dunlop O, Birkland K, Bruum JN. Prevalence of Hypertension in HIV-positive patient on HAART compared with HAART-nạve and HIV negative controls. Results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Dis;
2003; 22(12); 731-736.
48. Baekken M, Ingrid O, Sandvik L, Oektedalen O. Hypertension in an urban HIV-positive population compared with the general population; influence of combination antiretroviral therapy. Journal of Hypertension; 2008; 26(11); 2126-2133.
49. Crook T, Ahuja D, Modesir CZ. A case control study of the prevalence of hypertension in HIV-infected population compared to a healthy age, sex and race matched control group.
Toronto; AIDS 2006. Abstract number 2006- WEP0226.
50. National Cholesterol Education Program: ATP III guidelines at-a-glance quick desk reference. Bethesda, MD: National Institutes of Health; 2001. Available:
www.nhlbi.nih.gov/guidelines/cholesterol/atglance.pdf (accessed 2010 JUNE 10).
51. Knobel H, Jerico C, Montero M, Sorli ML, Velat M, Guelar A, et al. Global cardiovascular risk in patients with HIV infection: concordance and difference in estimates according to three risk equations (Framingham, SCORE, PROCAM ) AIDS Patient care STD’s;2007;21:452-457.
116 52. Anastos K, Lu D, Shi Q, Tien PC, Kaplan RC, Hessol NA et al. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.J Acquir Immune Defic Syndr. 2007; 45:34–42.
53. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy hyperlipidaemia, and insulin resistance. Lancet 1998, 351; 1881–1883.
54. Dubé MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, et al; Adult AIDS Clinical Trials Group Cardiovascular Subcommittee; HIV Medical Association of the Infectious Disease Society of America. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003; 37:613– 627.
55. Crum-Ciafone, Teridor R, Medina S, Barahona I, Ganesan A. Obesity among HIV patients:
The latest epidemic. AIDS Patient Care STDS.2008:22(12):925-930.
56. Amorosa V, Synnestvedt M, Gross R, et al. A tale of 2 epidemics. The intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr. 2005; 39:557–
561.
57. Kaplan RC, Kingsley LA, Sharrett AR, Lazar J, Tien PC, Mack WJ et al. Ten-year predicted heart disease risk in HIV-infected men and women. Clin Infect Dis.2007;
45:1074-1081.
58. Han TS, Sattar N, Lean M. ABC of Obesity. Assessment of obesity and its clinical implications. BMJ 2006; 333: 695-698.
59. King H, Aubert RE, Herman WH. Global Burden of Diabetes, 1995–2025. Prevalence numerical estimates and projections. Diabetes Care 1998; 21: 1414–1431.
117 60. Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study.
Arch Intern Med. 2005; 165:1179 –1184.
61. Visnegarwala F, Chen L, Raghavan S, Tedaldi E. Prevalence of diabetes mellitus and dyslipidemia among antiretroviral naive patients co-infected with hepatitis C virus (HCV) and HIV-1 compared to patients without co-infection. J Infect. 2005; 50:331–337.
62. Shlay JC, Bartsch G, Peng G, Wang J, Grunfeld C, Gilbert CL et al. Long term body composition and metabolic changes in antiretroviral nạve persons randomized to protease inhibitor, non nucleoside reverse transcriptase inhibitor or protease inhibitor plus non nucleoside reverse transcriptase inhibitor based strategy. J Acquir Immune Defic Syndr.2007, 44:506-517.
63. Dubé MP, Qian D, Edmondson-Melancon H. Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis. 2002; 35:475-481.
64. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome – a new worldwide definition.
Lancet 2005; 366:1059-1062.
65. Meigs JB, D’Agostino RB, Wilson PW. Risk variable clustering in the insulin resistance syndrome: the Framingham Offspring Study. Diabetes 1997; 46: 1594-1600.
66. Bruno R, Gazzaruso C, Sacchi P, Zocchetti C, Giordanetti C, Garzaniti A et al. High prevalence of metabolic syndrome among HIV-infected patients: link with the cardiovascular risk. J Acquir Immune Defic Syndr. 2002; 31: 363-365.
67. Rafael da Silva EF, Bassichetto KC, Lewi DS, Lipid Profile, Cardiovascular Risk Factors and Metabolic Syndrome in a Group of AIDS Patients. Arq Bras Cardiol 2009; 93(2):107-111.
118 68. Hsue PY, Lo JC, Franklin A, Bolger AF, Martin JN, Deek SG. Progression of atherosclerosis as assessed by Carotid intima-media thickness in patients with HIV-infection. Circulation 2004, 109(13):1603-1608.
69. Depairon M, Chessex S, Sudre P. Premature atherosclerosis in HIV-infected individuals:
focus on protease inhibitor therapy AIDS 2001, 15:329–334.
70. Lichtenstein K, Balasubramanyam A, Sekhar R, Freedland E. HIV-associated adipose redistribution syndrome (HARS): definition, epidemiology and clinical impact: AIDS Research and Therapy 2007,4:16.
71. Wohl DA, Body shape, lipid, and cardiovascular complications of HIV therapy. Curr HIV/AIDS Rep 2005, 2:74-82.
72. Duran S, Saves M, Spire B, Cailleton V, Sobel A, Carrieri P: Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy: AIDS 2001, 15:2441-2444.
73. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon: Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998, 351:871-875.
74. Bergersen BM, Sandvik L, Bruun JN: Body composition changes in 308 Norwegian HIV-positive patients. Scand J Infect Dis 2004, 36:186-191.
75. Bachetti P, Gripshover B, Grunfeld C, Heymsfield S, McCreath H, Tien P. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005, 40:121-131.
76. Agaba EI, Agaba PA, Sirisina ND. Renal disease in the acquired immunodeficiency syndrome in north central Nigeria. Niger J Med. 2003; July-September 12(3): 120-125.
77. Niaura R, Shadel W.G, Morrow K. Human immunodeficiency virus infection, AIDS and smoking cessation, the time is now. Clin Infect Dis 2000; 31(3):808-812.
78. Colditz JA. A meta-analysis of physical activity in the prevention of coronary heart disease.
Am J Epidemiol 1990; 132:612-628.
119 79. Pilote L, Dasgupta K, Guru V, Humphries KH, McGrath J, Norris C, et al. A comprehensive view of sex-specific issues related to cardiovascular disease. CMAJ 2007; 176 (6).
doi:10.1503/cmaj.051455.
80. Friis-Møller N, Thiébaut R, Reiss P, El-Sadr W, Weber R, D’Armini, Monforte A, Fontas E, Worm S, Kirk O, Phillips A, Sabin CA, Lundgren, JD, Law M, for the D:A:D Study Group. Predicting the risk of coronary, heart disease (CHD) in HIV-infected patients: the D:A:D CHD Risk, Equation. Paper presented at: 14th Conference on Retroviruses and Opportunistic Infections; February 27, 2007; Los Angeles, Calif.
81. Ferrer E, Minguez C, Marino A, Ceijo P, Brun F, Sanz J et al. Cardiovascular risk estimation in Spanish HIV-infected patients: a multicenter cohort study. Journal of International AIDS society 2008:11:92.
82. D’Agostino RB, Grundy S, Sullivan LM, Wilson P; CHD Risk Prediction Group.
Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001; 286:180-187.
83. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories Circulation. 1998; 97:1837–1847.
84. Wang X, Chai H, Yao Q, Chen C. Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction. J Acquir Immune Defic Syndr. 2007; 44:493– 499.
85. Grundy SM, Pasternak R, Greenland P, Smith SJ, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 1999; 100:1481-1492.
86. Yunis NA, Stone VE . Cardiac manifestations of HIV/AIDS: A review of Disease Spectrum and Clinical Management . J.Acquir Immune Defic Synd. Hum Retrovirol 1998,18:145 -154.
120 87. Hecth SR, Berger M, VanTosh A, et al. Unsuspected Cardiac abnormalities in the Acquired
Immune Deficiency syndrome: an echocardioraphic study. Chest. 1989;96:805-808.
88. Prenderast BD. HIV and Cardiovascular Medicine. Heart 2003; 89:793-800.
89. Levy WS, Simon GL. Rios JC et al. Prevalence of Cardiac abnormality in HIV Infection.
AM J Cardiol 1989,63: 86-89.
90. Lewis W. Cardiomyopathy in AIDS: a pathophysiological perspective. Pro Cardiovasc Dis 2000; 43: 151-170.
91. Silva-Cardoso J, Moura B, Martins L et al. Left ventricular dysfunction in HIV- infected patients. Int J. Cardiol 1998; 63: 37-45.
92. Anderson DW, Virmani R. Emerging Patterns of heart disease in Human Immunodeficiency Virus Infection. Hum Pathol 1990; 21:253-259.
93. Nzoubontane D, D, Blackett KN, Kuaban C. Cardiac Involvement in HIV Infected people in Yaounde Cameroon. Postgrad Med J 2002; 78:678-681.
94. Herskowitz A, Vlahov D, Willoughby S et al. Prevalence and Incidence of Left Ventricular Dysfunction in Human Immunodeficiency Virus Infection. Am J Cardiol 1993; 71:955-958.
95. Jacob AJ, Boon NA. The role of HIV in heart disease. In : Banatvala J, ed. Viruses and the heart. Edward Arnold, Sevenoaks, 1993:176-95.
96. Reilly JM, Cunnion RE, Anderson DW. Frequency of myocarditis, left ventricular dysfunction and ventricular tachycardia in the acquired immune deficiency syndrome. Am J Cardiol 1988; 62:789-793.
97. Barbaro G, Lorenzo G, Grisorio B, et al. Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV positive patients. N Engl J Med 1998; 339:1093-9.
98. Barbaro G. Cardiovascular manifestations of HIV infection. Circulation 2002; 106: 1420-1425.
121 99. Currie PF, Boon NA. Human immunodeficiency virus infection and the heart. In McMurray
JJV, Cleland JGF eds. Heart failure in clinical practice. Martin Dunitz 1996;2:85-108.
100. Barbaro G, Fisher SD, Pellicelli AM.The expanding role of the cardiologist in the care of HIV infected patients. Heart 2000; 86:365-7.
101. Pancharuniti N, Lewis CA, Sauberlich HE, Perkins LL, Go RCP, Alvarez JO et al Plasma homocysteine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr 1994; 59:940-948.
102. Lipsultz SE, Dilated cardiomyopathy in HIV-infected patients [editorial]. N Engl J Med 1998;339:1153-1155.
103. Lipshultz SE, Easley KA, Orav EJ, et al. Cardiac dysfunction and mortality in HIV-infected children. The prospective P2C2 HIV multicenter study. Circulation 2000;102;1542-8.
104. Levy WS, Simon GL. Rios JC. Prevalence of Cardiac abnormality in HIV Infection. AM J Cardiol 1989, 63: 86-89.
105. Himelman R, Chung W, Chernoff N et al. Cardiac manisfestations of human immunodeficiency virus infection: a two dimensional echocardiography study. J Am Coll Cardiol 1989; 13: 1030-6.
106. Blanchard DG, Hagenhoff C, Chow LC. Reversibility of cardiac abnormalities in human immunodeficiency virus (HIV)-infected individuals; a serial echocardiograph study. J Am coll Cardiol 1991; 17:1270-1276.
107. Corallo S, Mutinelli MR, Moroni M, et al. Echocardiography detects myocardial damage in AIDS: prospective study in 102 patietns. Eur Heart J 1988; 9:887-892.
108. Mulligan K, Grunfeld C, Tai VW et al. Hyperlipidaemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000; 23: 35-43.
122 109. Curie P, Ashok J, Foreman A. Heart muscle disease related to HIV infection; prognostic
implications. BMJ 1994; 390: 1605-7.
110. Rerkpattanapipat P, Wongpraprut N, Jacobs L et al. Cardiac manisfestations of acquired immunodefiency syndrome. Arch Intern Med 2000; 160: 602-608.
111. Longo-Mbenza B, Seghers L, Vita E, et al. Assessment of ventricular diastolic function in AIDS patients from Congo: a Doppler echocardiographic study. Heart 198; 80:184–9.
112. Omotoso ABO, Opadijo OG, Araoye MA. The evolving role of HIV infection in Dilated Cardiomyopathy in Nigerians. Trop Card 2000;26: 85-87.
113. Okeahialam BN, Anjorin FL. Echocardiographic study of the heart in AIDS. The Jos experience. Trop Card 2000; 26:3-6.
114. Danbauchi SS, Sani SG, Alhassan MA et al. Cardiac manifestations of stage III/IV HIV/AIDS compared to subjects on ARV in Zaria, Nigeria. Nig J Cardiol 2006; 3:5-10.
115. Olusegun-Joseph DA, Ajuluchukwu JN, Okany CC, Mbakwem AC, Oke DA, Okubadejo NV. Echocardiographic patterns in treatment nạve HIV-positive patients in Lagos, south west Nigeria. Cardiovasc J Afri 2012; 23(8): e1-6.
116. Lewis W. AIDS: cardiac findings from 115 autopsies. Prog Cardiovasc Dis 1989; 32: 207-215.
117. Jacob AJ, Sutherland GR, Bird AG, et al. Myocardial dysfunction in patients infected with HIV:prevalence and risk factors. Br Heart J 1992;68:549-553.
118. Himelman RB, Doerman M, Goodman P et al. Severe pulmonary hypertension and cor-pulmonale in the acquired immunodeficiency syndrome. Am J Cardiol 1989;64: 1396-1399.
119. Coplan NL, Shimony RY, Loachim HL et al. Primary pulmonary hypertension associated with human immunodeficiency virus infection. Ann J Med 1990; 89: 906-909.
120. Fink L, Reichek N, Sutton MG. Cardiac abnormalities in acquired immune deficiency syndrome. Am J Cardiol 1984; 54:1161-1163.
123 121. Gullestad L, Aass H, Fjeld J.G et al. Immunomodulating therapy with intravenous
immunoglobulin in patients with chronic heart failure. Circulation 2001; 103:220-225.
122. Heidenreich PA, Eisenberg MJ, Kee LL et al. Pericardial effusion in AIDS: Incidence and Survival. Circulation 1995:92:3229-34.
123. Silva-Cardoso J, Moura B , Martins L, et al. Pericardial involvement in Human Immunodeficiency Virus infection. Chest 1999:115:418-22.
124. Cegielski JP, Ramiya K, Lallinger GJ et al. Pericardial disease and Human Immunodeficiency Virus in Dares Salaam, Tanzania. Lancet 1990:335:209.
125. Sa I, Moco R, Cabral S, et al Constrictive pericarditis of tuberculous etiology in the HIV positive patient: case report and review of the literature. Rev Port Cardiol. 2006 Nov;
25(11):1029-38.
126. Nahass RG, Weinstein MP, Bartels J et al. Infective endocarditis in intravenous drug users:
a comparison of HIV type 1 negative and positive patients. J Infect Dis. 1990; 162:967-970.
127. Maqula NP, Mayosi BM. Cardiac involvement in HIV-infected people living in Africa: a review. Cardiovasc J S Afr 2003; 14(5): 231-237.
128. Reuter H, Burgess LJ, Doubell AF. Epidemiology of pericardial effusions at a large academic hospital in South Africa. Epidemiol Infect. 2005; 133:393-399.
129. Holladay AO, Siegel RJ, Schwartz DA. Cardiac malignant lymphoma in acquired immune deficiency syndrome. Cancer. 1992;70:2203-2207.
130. Sunderam G, McDonald RJ , Maniatis T, et al. Tuberculosis as a manifestation of the Acquired Immunodeficiency Syndrome(AIDS).JAMA 1986;256:362-366.
131. Stotka JL, Gord CB, Downer WR et al .Pericardial effusion and Tamponade due to Kaposi sarcoma in Acquired Immunodeficiency Syndrome. Chest 1989; 95:1359-1361.
132. Neumann T, Canbay A, Barkhausen M, et al. Paracardial lipodystrophy versus pericardial effusion in HIV positive patients. Heart 2002; 87: e4.
124 133. Ntseke M, Hakim J. Impact of Human Immunodeficiency Virus Infection on Cardiovascular
Disease in Africa. Circulation 2005;112:3602-3607.
134. Ntseke M, Wiysonge C, Volmink JA et al. Adjuvant corticosteroids for tuberculous pericarditis: promising, but not proven. QJM 2003; 96: 593-599.
135. Okeahilam B.N, Babashani M.B. Infective Endocarditis in AIDS. Trop Card.2001;
27(108):68-69.
136. Barbaro G, Di Lorenzo G, Grisorio B, et al. Cardiac involvement in acquired immunodeficiency syndrome. A multi-centre clinical-pathological study. AIDS Res Hum Retroviruses 1998;14:827-38.
137. Austran B, B, Gorin I, Leibowitch M et al. AIDS in a Haitian woman with cardiac Kaposi’s sarcoma and Whipple disease. Lancet 1983; 1: 767-768.
138. Ambrose RA, Eun-Young L, Sharer LR et al. The acquired immunodeficiency syndrome in intravenous drug abusers and patients with a sexual risk. Hum Pathol 1987;18:1109-1114.
139. Constantino A, West TE, Gupta M, et al. Primary cardiac lymphoma in a patient with acquired immune deficiency syndrome. Cancer 1987;60:2801-2805.
140. Kim KK, Factor SM. Membranoproliferative glomerulonephritis and plexogenic pulmonary arteriopathy in a homosexual man with acquired immunodeficiency syndrome. Hum Pathol.
1987;18:1293-1296.
141. Mesa RA, Edell ES, Dunn WF, et al. Human immunodeficiency virus infection and pulmonary hypertension. Mayo Clin Proc. 1998; 73:37-44.
142. Meta NJ, Khan IA, Mehta RN, et al. HIV-related pulmonary hypertension: analytic review of 131 cases. Chest 2000; 118:1133-41.
143. Lipshultz SE, Chanock S, Sanders SP. Cardiovascular manifestations of Human immunodeficiency virus infection in infants and children. Am J Cardiol 1989; 63:1489-1497.